Wilcox MH - Search Results

1

Hospital disinfectants and spore formation by Clostridium difficile.

Wilcox MH, Fawley WN. Wilcox MH, et al. Lancet. 2000 Oct 14;356(9238):1324. doi: 10.1016/S0140-6736(00)02819-1. Lancet. 2000. PMID: 11073024

2

Ciprofloxacin and Clostridium difficile infection.

Bates CJ, Wilcox MH, Spencer RC, Harris DM. Bates CJ, et al. Among authors: wilcox mh. Lancet. 1990 Nov 10;336(8724):1193. doi: 10.1016/0140-6736(90)92808-u. Lancet. 1990. PMID: 1978050 No abstract available.

3

Cleaning up Clostridium difficile infection.

Wilcox MH. Wilcox MH. Lancet. 1996 Sep 21;348(9030):767-8. doi: 10.1016/S0140-6736(05)65204-X. Lancet. 1996. PMID: 8813978 No abstract available.

4

Evaluation of a novel endoluminal brush method for in situ diagnosis of catheter related sepsis.

Kite P, Dobbins BM, Wilcox MH, Fawley WN, Kindon AJ, Thomas D, Tighe MJ, McMahon MJ. Kite P, et al. Among authors: wilcox mh. J Clin Pathol. 1997 Apr;50(4):278-82. doi: 10.1136/jcp.50.4.278. J Clin Pathol. 1997. PMID: 9215141 Free PMC article.

5

Recurrence of symptoms in Clostridium difficile infection--relapse or reinfection?

Wilcox MH, Fawley WN, Settle CD, Davidson A. Wilcox MH, et al. J Hosp Infect. 1998 Feb;38(2):93-100. doi: 10.1016/s0195-6701(98)90062-7. J Hosp Infect. 1998. PMID: 9522287

6

Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam.

Settle CD, Wilcox MH, Fawley WN, Corrado OJ, Hawkey PM. Settle CD, et al. Among authors: wilcox mh. Aliment Pharmacol Ther. 1998 Dec;12(12):1217-23. doi: 10.1046/j.1365-2036.1998.00428.x. Aliment Pharmacol Ther. 1998. PMID: 9882029 Clinical Trial.

7

Value of lysozyme agar incorporation and alkaline thioglycollate exposure for the environmental recovery of Clostridium difficile.

Wilcox MH, Fawley WN, Parnell P. Wilcox MH, et al. J Hosp Infect. 2000 Jan;44(1):65-9. doi: 10.1053/jhin.1999.0253. J Hosp Infect. 2000. PMID: 10633056

8

In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates.

Wilcox MH, Fawley W, Freeman J, Brayson J. Wilcox MH, et al. J Antimicrob Chemother. 2000 Oct;46(4):551-6. doi: 10.1093/jac/46.4.551. J Antimicrob Chemother. 2000. PMID: 11020251

9

Virulence of Clostridium difficile toxin A negative strains.

Wilcox MH, Fawley WN. Wilcox MH, et al. J Hosp Infect. 2001 May;48(1):81. doi: 10.1053/jhin.2000.0917. J Hosp Infect. 2001. PMID: 11358476 No abstract available.

10

Extremely low prevalence of UK Staphylococcus aureus isolates with reduced susceptibility to vancomycin.

Wilcox MH, Fawley W. Wilcox MH, et al. J Antimicrob Chemother. 2001 Jul;48(1):144-5. doi: 10.1093/jac/48.1.144. J Antimicrob Chemother. 2001. PMID: 11418529 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

469 results

Search Page

Filters